Clinical guidelines on the management of hepatitis C

Gut

Volumn 49, Issue SUPPL. 1, 2001, Pages

  Booth, J C L ^a   O'Grady, J ^b   Neuberger, J ^c  

^a ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; METHADONE; PLACEBO; RIBAVIRIN;

ALGORITHM; BLOOD TOXICITY; CLINICAL TRIAL; COUNSELING; DISEASE COURSE; DISEASE SEVERITY; DISEASE TRANSMISSION; DOSE RESPONSE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; META ANALYSIS; NEPHROTOXICITY; NEUROTOXICITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEROLOGY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; FEMALE; GENES, VIRAL; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; PROGNOSIS; RECURRENCE;

EID: 0034950181     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (177)

1. Hepatitis C virus: The major causative agent of viral NANB hepatitis
2. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis
3. Hepatitis C virus antibodies among risk groups in Spain
4. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis
5. Antibodies to HCV
6. Anti-hepatitis C antibodies and NANB post-transfusion hepatitis in Netherlands
7. Detection of hepatitis C sequences in non-A, non-B hepatitis
8. The natural history of community-acquired hepatitis C in the United States
9. Hepatitis C virus infection in the asymptomatic British blood donor
10. High level of hepatitis C endemicity in Gabon, equatorial Africa
11. Hepatitis C virus infection in Egyptian volunteer blood donors in Riyadh
12. Incidence of hepatitis C virus in Egyptians
13. The elusive hepatitis C virus
14. Evidence for persistent hepatitis C virus (HCV) infection in haemophiliacs
15. Long-term clinical and histological follow up of chronic posttransfusion hepatitis
16. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis
17. Anti-HCV positive patients in dialysis units
18. Anti-HCV positive patients in dialysis units
19. Transmission of hepatitis C virus by organ transplantation
20. Hepatitis C in hospital employees with needle stick injuries
21. Prevalence of hepatitis C antibodies in clinical health-care workers
22. Sexual transmission of hepatitis C virus: Cohort study (1981-9) among European homosexual men
23. Hepatitis C virus: Evidence for sexual transmission
24. Hepatitis C virus and sexual transmission
25. Hepatitis C in HIV-infected patients with and without AIDS: Prevalence and relationship to patient survival
26. Sexual transmission of hepatitis C virus
27. The pathology of hepatitis C as a function of mode of transmission: Blood transfusion vs intravenous drug use
28. Failure to detect hepatitis C virus genome in human secretions with the polymerase chain reaction
29. Intrafamilial and sexual transmission of hepatitis C virus
30. Molecular analysis of intraspousal transmission of hepatitis C virus
31. Hepatitis C virus infection in spouses of patients with type C chronic liver disease
32. Sexual transmission of HCV
33. Risk factors associated with hepatitis C virus (HCV) infection among prostitutes and their clients in the city of Santos, Sao Paolo State, Brazil
34. Maternal-infant transmission of hepatitis C virus and HIV infections: A possible interaction
35. Transmission of hepatitis C virus from mothers to infants
36. Mother-to-infant transmission of hepatitis C virus
37. Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin
38. Human immunodeficiency virus infection as risk factor for mother to child hepatitis C virus transmission; persistence of anti-hepatitis C virus in children is associated with the mother's anti-hepatitis C virus immunoblotting pattern
39. Hepatitis C virus RNA in saliva and breastmilk of hepatitis C carrier mothers
40. Detection of HCV RNA in saliva, urine, seminal fluid and ascites
41. Hepatitis C virus RNA in saliva of patients with posttransfusion hepatitis and low efficiency of transmission among spouses
42. Experimental transmission of NANB hepatitis by saliva
43. Search for intrafamilial transmission of hepatitis C virus in haemophilia patients
44. High prevalence of antibodies to hepatitis C virus among family members of patients with anti-HCV positive chronic liver disease
45. Hepatitis C virus not found in fulminant non-A, non-B hepatitis
46. Exclusion in liver by polymerase chain reaction of hepatitis B and C viruses in acute liver failure attributed to sporadic non-A, non-B hepatitis
47. Coinfection with hepatitis B and C, C and D viruses results in severe chronic liver disease and responds poorly to interferon-α treatment
48. Long-term mortality after transfusion-associated non-A, non-B hepatitis
49. Clinical outcomes after transfusion-associated hepatitis C
50. HCV viraemia and liver injury in symptom-free blood donors
51. Severity of liver disease with different HCV clones
52. Degree of diversity of hepatitis C virus quasispecies and progression of liver disease
53. Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma - Its relationship to alcohol drinking and the age of transfusion
54. Hepatitis C infection in patients with primary hypogammaglobulinaemia after treatment with contaminated immune globulin
55. Hepatitis C viremia and anti-HCV antibodies in alcoholics
56. The alcohol-altered liver membrane antibody and hepatitis C virus infection in the progression of alcoholic liver disease
57. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection
58. Natural history of liver fibrosis progression in patients with chronic hepatitis C
59. Morbidity and mortality in compensated cirrhosis C: A retrospective follow-up study of 384 patients
60. Hepatitis C virus and autoimmunity: Fortuitous association or reality?
61. Cryoglobulinaemia and hepatitis C infection
62. High prevalence of hepatitis C virus RNA in the supernatant and the croprecipitate of patients with essential and secondary type II mixed cryoglobulinaemia
63. Cryoglobulinaemia with vasculitis associated with hepatitis C virus infection
64. HCV-associated idiopathic thrombocytopenic purpura (ITP)
65. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis
66. Hepatitis C virus antibodies in chronic alcoholic patients: Association with severity of liver injury
67. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C
68. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma
69. Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma
70. Antibodies to hepatitis C virus in patients with hepatocellular carcinoma
71. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African Blacks
72. Prevalence of hepatocellular carcinoma in patients with alcoholic cirrhosis and prior exposure to hepatitis C
73. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis
74. Isolation of a cDNA clone derived from a blood-borne viral hepatitis genome
75. Improved detection of anti-HCV in post-transfusion hepatitis by a third generation ELISA
76. Re-instatement of donors who test false-positive in second generation hepatitis C virus enzyme immunoassay should await availability of licensed third-generation tests
77. Significance of NS3 and NS5 antigens in screening for HCV antibody
78. Temporal relationships of hepatitis C virus RNA and antibody responses following experimental infection of chimpanzees
79. Follow-up of hepatitis C virus infection in chimpanzees: Determination of viraemia and specific humoral immune response
80. Improved detection of hepatitis C virus antibodies in high-risk populations
81. Improved serodiagnosis of chronic hepatitis C in Japan by a second-generation enzyme-linked immunosorbent assay
82. Detection of HCV infection with second-generation assays
83. Serological response and detection of viraemia in acute hepatitis C virus infection
84. HCV confirmatory testing of blood donors
85. HCV and PCR negativity
86. Detection of HCV infection by four diagnostic systems: First-generation and second-generation enzyme-linked immunosorbent assay, second-generation recombinant immunoblot assay and nested polymearse chain reaction
87. Indeterminate hepatitis C
88. Hepatitis C in blood donors
89. Indeterminate hepatitis C
90. Clinical importance of HCV confirmatory testing in blood donors
91. Indeterminate second-generation hepatitis C recombinant immunoblot test: Detection of hepatitis C virus infection by polymerase chain reaction
92. Highly positive c22-3 "indeterminate" second generation RIBA: Resolution by third generation RIBA and HCV RNA PCR
93. HCV infection assessed with third generation anti-HCV testing and polymerase chain reaction
94. Indeterminate third generation recombinant immunoblot assay in hepatitis C virus infection
95. Enhanced detection by PCR of hepatitis C virus RNA
96. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection
97. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV
98. Relationship of aminotransferases to liver histological status in chronic hepatitis C
99. High rate of infectivity and liver disease in blood donors with antibodies to HCV
100. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV
101. The utility of liver biopsy in diagnosis of hepatitis C
102. Serum HCV RNA levels in chronic HCV hepatitis measured by quantitative PCR assay; correlation with serum AST
103. Improved quantitative PCR using nested primers
104. Quantitative PCR
105. Sequence variability in the 5′ non-coding region of hepatitis C virus: Identification of a new virus type and restrictions on sequence diversity
106. At least five related, but distinct, hepatitis C viral genotypes exist
107. Sequence analysis of the 5′ noncoding region of hepatitis C virus
108. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region
109. Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): Use of type-specific peptides to serologically differentiate infections with HCV types 1, 2 and 3
110. At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide
111. Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions
112. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources
113. Detection of three types of hepatitis C virus in blood donors: Investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities
114. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay
115. Hepatitis C virus genotypes: An investigation of type-specific differences in geographic origin and disease
116. Chronic hepatitis C virus infections: Predictive value of genotype and level of viraemia on disease progression and response to interferon-α
117. HCV genotypes in chronic hepatitis C and response to interferon
118. Factors predictive of response to interferon-α therapy in hepatitis C virus infection
119. Spread of hepatitis C virus among sexual partners of HCVAb positive intravenous drug users
120. Heterosexual transmission of hepatitis C virus
121. Intrafamilial transmission of hepatitis C virus: The important role of infections between spouses
122. Management of chronic hepatitis C: Clinical audit of biopsy based management algorithm
123. Hepatitis C and haemophilia
124. Meta-analysis of interferon randomised trials in the treatment of viral hepatitis C: Effects of dose and duration
125. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis
126. Treatment with interferon(s) of community-aquired chronic hepatitis and cirrhosis type C
127. Treatment of chronic hepatitis C with high dose interferon alpha-2b. A multicenter study
128. 2b
129. A comparison of three interferon alpha-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis
130. Sustained response after alpha interferon therapy in patients with chronic hepatitis C
131. A prospective randomised trial comparing lymphoblastoid to recombinant interferon alfa-2a as therapy for chronic hepatitis C
132. Comparative study. Lymphoblastoid interferon alpha-n1 improves long term response to a 6 month course of treatment in chronic hepatitis C compared with recombinant interferon alpha-2b. Results of an international randomized controlled trial
133. Ribavirin treatment for chronic hepatitis C
134. A pilot study of ribavirin therapy for chronic hepatitis C
135. Ribavirin as monotherapy for chronic hepatitis C: A randomised, double-blind, placebo-controlled trial
136. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial
137. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study
138. A pilot study of combination therapy with ribavirin plus interferon alpha for interferon alpha-resistant chronic hepatitis C
139. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centres
140. Combined alpha-interferon and ribavirin treatment for chronic hepatitis C infection
141. The effect of interferon alpha and ribavirin combination therapy in naive patients with chronic hepatitis C
142. Randomised, double-blind, placebo-controlled trial of inteferon α-2b with and without ribavirin for chronic hepatitis C
143. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C
144. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
145. Histological grading and staging of chronic hepatitis
146. Management of the asymptomatic HCV carrier with normal ALT levels
147. Interferon alpha therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity
148. Comparative efficacy of interferon alpha in cirrhotic and non-cirrhotic patients with non-A non-B hepatitis
149. Interferon treatment of cirrhotic patients with chronic hepatitis C
150. Alpha-interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis
151. Effectiveness of interferon alpha on incidence of hepatocellular carcinoma and decompensation in European patients with cirrhosis type C
152. Factors predictive of the response to interferon in patients with chronic hepatitis C
153. Response to interferon-α therapy is influenced by the iron content of the liver
154. Hepatitis C virus serotype II responds more favorably to interferon-α therapy
155. Factors predictive of a beneficial response to therapy of hepatitis C
156. Efficacy of interferon dose and factors predictive of sustained response in chronic hepatitis C: Final results of a Benelux study in 350 patients
157. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy
158. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C
159. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients
160. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients
161. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b
162. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomised multicenter trial
163. Is there an optimal time to measure quantitative HCV RNA to predict outcome following interferon treatment for chronic HCV infection?
164. Therapy of hepatitis C: Re-treatment with alpha interferon
165. Sequential versus concomitant administration of ribavirin and interferon alpha-n3 in patients with chronic hepatitis C not responding to interferon alone: Results of a randomised, controlled trial
166. Interferon alpha with ribavirin for the treatment of chronic hepatitis C in non-responders or relapsers to interferon monotherapy
167. Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the treatment of chronic hepatitis C: A randomised clinical trial
168. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
169. Estimates of the cost-effectiveness of a single course of interferon alfa-2b in patients with histologically mild chronic hepatitis C
170. Treatment of chronic type B and C hepatitis with interferon alfa: An economic appraisal
171. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: Life table method applied to health authority population
172. Cost-benefit analysis of long term haemodialysis for chronic renal failure
173. The cost-effectiveness of enalapril in the treatment of chronic heart failure
174. Cost-effectiveness of initial ribavirin/interferon alfa-2b for chronic hepatitis C
175. Treatment of naive patients with chronic hepatitis C